1. Home
  2. EEX vs XERS Comparison

EEX vs XERS Comparison

Compare EEX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Emerald Holding Inc.

EEX

Emerald Holding Inc.

HOLD

Current Price

$4.99

Market Cap

890.6M

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.23

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EEX
XERS
Founded
2013
2005
Country
United States
United States
Employees
821
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
890.6M
1.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EEX
XERS
Price
$4.99
$6.23
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$7.70
$10.83
AVG Volume (30 Days)
587.6K
1.6M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
1.27%
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.01
Revenue
N/A
$49,590,000.00
Revenue This Year
$7.49
$34.37
Revenue Next Year
$6.81
$22.86
P/E Ratio
$236.96
$590.00
Revenue Growth
N/A
142.67
52 Week Low
$3.32
$4.30
52 Week High
$5.45
$10.08

Technical Indicators

Market Signals
Indicator
EEX
XERS
Relative Strength Index (RSI) 57.90 50.83
Support Level $4.81 $5.79
Resistance Level $5.10 $6.41
Average True Range (ATR) 0.15 0.31
MACD 0.01 -0.04
Stochastic Oscillator 85.83 31.49

Price Performance

Historical Comparison
EEX
XERS

About EEX Emerald Holding Inc.

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: